Long-term Fluoxetine Treatment Induces Input-specific LTP and LTD Impairment and Structural Plasticity in the CA1 Hippocampal Subfield
Overview
Authors
Affiliations
Antidepressant drugs are usually administered for several weeks for the treatment of major depressive disorder. However, they are also prescribed in several additional psychiatric conditions as well as during long-term maintenance treatments. Antidepressants induce adaptive changes in several forebrain structures which include modifications at glutamatergic synapses. We recently found that repetitive administration of the selective serotonin reuptake inhibitor (SSRI) fluoxetine to naïve adult male rats induced an increase of mature, mushroom-type dendritic spines in several forebrain regions. This was associated with an increase of GluA2-containing α-amino-3-hydroxy-5-methylisoxazole-4-propionate receptors (AMPA-Rs) in telencephalic postsynaptic densities. To unravel the functional significance of such a synaptic re-arrangement, we focused on glutamate neurotransmission in the hippocampus. We evaluated the effect of four weeks of 0.7 mg/kg fluoxetine on long-term potentiation (LTP) and long-term depression (LTD) in the CA1 hippocampal subfield. Recordings in hippocampal slices revealed profound deficits in LTP and LTD at Schaffer collateral-CA1 synapses associated to increased spine density and enhanced presence of mushroom-type spines, as revealed by Golgi staining. However, the same treatment had neither an effect on spine morphology, nor on LTP and LTD at perforant path-CA1 synapses. Cobalt staining and immunohistochemical experiments revealed decreased AMPA-R Ca(2+) permeability in the stratum radiatum (s.r.) together with increased GluA2-containing Ca(2+) impermeable AMPA-Rs. Therefore, 4 weeks of fluoxetine treatment promoted structural and functional adaptations in CA1 neurons in a pathway-specific manner that were selectively associated with impairment of activity-dependent plasticity at Schaffer collateral-CA1 synapses.
The multifaceted effects of fluoxetine treatment on cognitive functions.
Ampuero E, Luarte A, Flores F, Soto A, Pino C, Silva V Front Pharmacol. 2024; 15:1412420.
PMID: 39081952 PMC: 11286485. DOI: 10.3389/fphar.2024.1412420.
Vega-Rivera N, Gonzalez-Trujano M, Luna-Angula A, Sanchez-Chapul L, Estrada-Camarena E Front Pharmacol. 2023; 14:1211663.
PMID: 37900157 PMC: 10613096. DOI: 10.3389/fphar.2023.1211663.
SALM4 negatively regulates NMDA receptor function and fear memory consolidation.
Lie E, Yeo Y, Lee E, Shin W, Kim K, Han K Commun Biol. 2021; 4(1):1138.
PMID: 34588597 PMC: 8481232. DOI: 10.1038/s42003-021-02656-3.
Zhu W, Yang F, Cai X, Zhang W, Zhang J, Cai M Naunyn Schmiedebergs Arch Pharmacol. 2020; 394(1):151-164.
PMID: 32444989 DOI: 10.1007/s00210-020-01845-x.
Optogenetic Control of Spine-Head JNK Reveals a Role in Dendritic Spine Regression.
Hollos P, John J, Lehtonen J, Coffey E eNeuro. 2020; 7(1).
PMID: 31937523 PMC: 7053173. DOI: 10.1523/ENEURO.0303-19.2019.